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Myocardial damage is one of the central pathophysi-ological processes in heart failure with reduced ejec-
tion fraction (HFrEF). Ongoing myocardial damage detected 
with standard and high-sensitivity troponin assays1–4 has been 
demonstrated during acute decompensation and in stable 
outpatients with HF.3 Higher detectable troponin concentra-
tions have been associated with abnormalities of cardiac struc-
ture and function5,6 and poorer prognosis in HFrEF.7 Heart 
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Background—Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart 
failure with reduced ejection fraction, but less is known about the association in heart failure with preserved ejection 
fraction.
Methods and Results—We examined the prevalence of elevated high-sensitivity troponin T (hs-TnT) in 298 patients 
with heart failure with preserved ejection fraction enrolled in the Prospective comparison of angiotensin receptor 
neprilysin inhibitor with angiotensin receptor blocker on Management Of heart failUre with preserved ejectioN fracTion 
(PARAMOUNT) trial, in which the angiotensin receptor neprilysin inhibitor LCZ696 reduced markers of heart failure 
severity compared with valsartan. We assessed the association between hs-TnT and cardiac structure and function, and 
the effect of LCZ696, compared with valsartan, on hs-TnT over 36 weeks. Elevated hs-TnT in the myocardial injury 
range (>0.014 μg/L) was found in 55% of patients and was associated with older age, history of diabetes mellitus, 
higher N-terminal pro-brain natriuretic peptide, lower estimated glomerular filtration rate, and larger left atrial size, 
left ventricular volume, and mass. LCZ696 treatment reduced hs-TnT to a greater extent at 12 weeks (12% reduction; 
P=0.05) and at 36 weeks (14% reduction; P=0.03) compared with valsartan.
Conclusions—Troponin T was elevated in a substantial number of patients enrolled in a heart failure with preserved 
ejection fraction clinical trial and was associated with abnormalities of cardiac structure, function, and elevated baseline 
N-terminal pro-brain natriuretic peptide. Decreases in hs-TnT with LCZ696 in parallel with improvement in N-terminal 
pro-brain natriuretic peptide and left atrial size suggest that the angiotensin receptor neprilysin inhibitor LCZ696 may 
reduce this measure of myocardial injury in heart failure with preserved ejection fraction.
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failure with preserved ejection fraction (HFpEF) accounts for 
up to 50% of cases of heart failure. While elevated troponin has 
been detected in hospitalized patients with HFpEF,8–10 whether 
troponin is detectable in stable outpatients with HFpEF, and 
whether elevations in troponin are related to abnormalities of 
cardiac structure and function, is unknown.10–13
The Prospective comparison of angiotensin receptor 
neprilysin inhibitor with angiotensin receptor blocker on 
Management Of heart failUre with preserved ejectioN fracTion 
(PARAMOUNT) trial was a phase II trial testing the safety 
and efficacy of LCZ696 in stable outpatients with HFpEF. 
PARAMOUNT demonstrated that LCZ696 reduced N-terminal 
pro-brain natriuretic peptide (NT-proBNP) at 12 weeks and 
left atrial size and New York Heart Association (NYHA) class 
at 36 weeks.14 We examined the prevalence and correlates of 
biochemical evidence of myocardial damage, detected using 
high-sensitivity troponin-T (hs-TnT), and whether therapy with 
LCZ696 affected hs-TnT in patients with HFpEF.
Methods
The design and results of the PARAMOUNT trial (registered at 
ClinicalTrials.gov, NCT00887588) have been previously published.14 
PARAMOUNT was a randomized, double-blind, parallel-group, 
active-controlled trial. Men and women aged ≥40 years with a left 
ventricular ejection fraction ≥45% and with a documented history 
of heart failure with associated signs or symptoms were eligible for 
randomization. Patients were required to have a NT-proBNP level of 
≥400 pg/mL at screening, be on diuretic therapy, and have a systolic 
blood pressure ≤140 mm Hg, or ≤160 mm Hg if on 3 or more blood 
pressure drugs at randomization, have an estimated glomerular filtra-
tion rate (eGFR) ≥30 mL/min per 1.73 m2 at screening, and a potassi-
um concentration ≤5.2 mmol/L. Treatment assignment was stratified 
by previous use of angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker and region. The primary end point was change 
in NT-proBNP from baseline to 12 weeks. The study protocol was 
approved by all individual site institutional review boards and ethics 
committees, and all recruited patients gave written informed consent.
NT-proBNP was measured at screening, randomization, week 4, 
week 12, and week 36 or at an earlier end of study visit if premature 
termination. NT-proBNP was measured at a central laboratory (Quest 
Diagnostics, Valencia, CA) with the Elecsys NT-proBNP immunoas-
say (Roche Diagnostics, Indianapolis, IN). Samples were taken for 
hs-TnT at randomization, 12 weeks and 36 weeks. Plasma hs-TnT 
was measured using the high-sensitivity Roche Elecsys assay (lot 
number 167345; Roche Diagnostics GmbH, Mannheim, Germany) 
at a central laboratory (Clinical Reference Laboratory-Europe Ltd, 
UK). The between-run variation of hs-TnT levels below the limit 
of quantification (0.013 μg/L) was not sufficiently high to permit 
analysis of the actual values. However, as a sensitivity analysis, we 
imputed a value of half the lower limit of quantification, as has been 
performed previously with this assay,15 and imputed a value near to 
the limit of quantification (0.012 μg/L) to limit any bias from im-
puting a value too far from the lowest measured value. All samples 
were stored at –80°C and analyzed in a batch. There was no differ-
ence between treatment groups in the duration of storage (P=0.70). 
A hs-TnT sample was available for 298 patients. Echocardiography 
was performed at screening, randomization, week 12, and week 36 
or at end of study or early termination visits. Analyses were con-
ducted at a core laboratory (Brigham and Women’s Hospital, Boston, 
MA). Measurements were made in triplicate in accordance with the 
recommendations of the American Society of Echocardiography.16 
Myocardial strain was analyzed, as previously described.13
Statistical Analysis
For patients with a hs-TnT value below the lower limit of quantifica-
tion (<0.013 μg/L), we imputed half the lower limit of quantification.15 
Correlation between hs-TnT and logNT-proBNP was assessed us-
ing the Spearman correlation. Associations between categories of 
hs-TnT and baseline variables were examined using t tests and χ2 
tests where appropriate, with the exception of NT-proBNP, which 
was tested using the Wilcoxon rank-sum test due to skewness, and 
NYHA class, which used the Fisher exact test. Associations between 
baseline variables and categories of change in hs-TnT from baseline 
to 36 weeks (decrease, no change, or increase) were conducted via 
trend test across change categories. NT-proBNP was assessed using 
the Cuzick nonparametric trend test. The end point of change in hs-
TnT was analyzed using multiple linear regression with postbaseline 
log-transformed hs-TnT as the outcome, randomized treatment and 
the stratification variables (previous use of an angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker, and region) as fixed 
factors, and the baseline log-transformed hs-TnT as a covariate. The 
distribution of hs-TnT was skewed (mean [SD] 0.0198 [0.0168] and 
median [IQR]=0.015[0.0065–0.027]); therefore, the values were log 
transformed. We examined the end point of change in hs-TnT using 
a binary outcome of hs-TnT>0.014 μg/L and hs-TnT ≤0.014 μg/L, 
ie, within or above the 99th centile of the general population and the 
cutoff used to define myocardial injury, using logistic regression ad-
justing for the variables above. As sensitivity analyses, we used linear 
regression models in which an alternate value (0.012) was imputed 
for those below the lower limit of quantification , and finally we per-
formed an analysis of change in hs-TnT that was insensitive to the 
value of hs-TnT imputed for the lower limit of quantification , ordi-
nal logistic regression adjusted for baseline log hs-TnT. We also per-
formed analyses incorporating both 12- and 36-week observations as 
repeated measures, using random intercept linear regression models 
and ordinal and binary logistic regression models with standard errors 
adjusted for clustered data. We examined interactions between treat-
ment and week of hs-TnT measurement (12 weeks and 36 weeks). 
Finally in a multivariable model (adjusting for age, sex, NYHA class, 
NT-proBNP, heart rate, body mass index, systolic blood pressure, 
eGFR, prior history or heart failure hospitalization, atrial fibrillation, 
myocardial infarction, ejection fraction, E/E′, left atrial volume index, 
left ventricular end-diastolic diameter), we assessed the predictors of 
baseline log hs-TnT and change in log hs-TnT at 12 and 36 weeks. All 
analyses were performed using STATA version 12 (StataCorp, College 
Station, TX). A P value of <0.05 was considered significant.
Results
At baseline, the majority of patients (164, 55%) had a hs-TnT 
level in the range consistent with myocardial injury (>0.014 μg/L; 
 Figure 1). Patients with an elevated hs-TnT were older, more 
likely to have a history of diabetes mellitus , had lower diastolic 
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Figure 1. High-sensitivity troponin T (hs-TnT) levels in the 
myocardial injury range. Proportion of individuals with a hs-
TnT>0.014 μg/L at baseline, 12 weeks and 36 weeks according 
to treatment group.
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blood pressure, and were less likely to be taking a β-blocker 
(Table1). In addition, those with higher hs-TnT had higher NT-
proBNP (r=0.43; P<0.001) and lower eGFR (r=–0.35; P<0.001).
We noted several differences in cardiac structure in patients 
with an elevated troponin (Table 2), including larger left atrial 
diameter, left ventricular volume, and greater left ventricular 
mass. We observed no differences in measures of cardiac sys-
tolic or diastolic function, including left ventricular ejection 
fraction, global longitudinal strain, E′, or E/E′ ratios among 
patients with and without elevated hs-TnT. Tricuspid regurgi-
tant velocity was higher in the group with an elevated hs-TnT.
Over the course of 36 weeks, hs-TnT fell in both the LCZ696 
and the valsartan groups (Figure 2), with the majority of patients 
still having a hs-TnT in the myocardial injury range (Figure 1). 
The characteristics of those whose hs-TnT level fell, remained 
unchanged, or increased are given in Table 3. Change in hs-TnT 
correlated with change in NT-proBNP at 36 weeks (r=0.35; 
P<0.001),but not at 12 weeks (r=0.12; P=0.06). We found no 
correlation between changes in systolic blood pressure and 
hs-TnT at 12 weeks (r=–0.09; P=0.15) and weak correlation 
between change in systolic blood pressure and hs-TnT at 36 
weeks (r=–0.15; P=0.03). There was no association between 
change in hs-TnT at 12 or 36 weeks and change in E′ (P=0.16 
and P=0.81, respectively) or change in E/E′ (P=0.11 and P=0.34, 
respectively). In a multivariable model, female sex (P=0.004), 
prior MI (P=0.016), and higher eGFR (P<0.001) were associ-
ated with lower hs-TnT at baseline, whereas higher NT-proBNP 
was associated with higher hs-TnT at baseline (P<0.001). At 12 
weeks, except for baseline hs-TnT, no variables were associ-
ated with change in hs-TnT. At 36 weeks in addition to baseline 
hs-TnT, NT-proBNP was associated with change in log hs-TnT 
(coefficient –0.14 per 1 log unit increase; P=0.002) as was age 
(coefficient 0.02 per 1 year increase; P<0.001), systolic blood 
pressure (coefficient –0.01 per 1 mm Hg change; P=0.008), 
eGFR (coefficient –0.01 per 1 mL/min/m2 increase; P<0.001), 
and E/E′ (coefficient 0.02 per 1 unit increase; P=0.02).
Compared with valsartan, treatment with LCZ696 was 
associated with greater reduction in hs-TnT (Tables 4 and 5; 
Table 1. Baseline Characteristics of the Cohort and by hs-TnT Group
Overall Cohort hs-TnT ≤0.014 μg/L hs-TnT >0.014 μg/L P Value
n=298 n=134 (45%) n=164 (55%)
hs-TnT ≤0.014 μg/L vs 
hs-TnT >0.014 μg/L
Age, y 71 (9) 70 (9) 72 (9) 0.01
Women, % 167 (56%) 86 (64%) 81 (49%) 0.01
NYHA Class
  NYHA Class I 2 (1%) 1 (1%) 1 (1%)
  NYHA Class II 236 (79%) 109 (81%) 127 (77%)
  NYHA Class III 60 (20%) 24 (18%) 36 (22%) 0.74
Prior history
  Previous admission to hospital for heart failure 126 (42%) 51 (38%) 75 (46%) 0.18
  History of atrial fibrillation 123 (41%) 57 (43%) 66 (40%) 0.69
  Atrial fibrillation at screening ECG 83 (28%) 41 (31%) 42 (26%) 0.36
  History of hypertension 280 (94%) 127 (95%) 153 (93%) 0.59
  History of diabetes mellitus 114 (38%) 40 (30%) 74 (45%) 0.01
  History of myocardial infarction 62 (21%) 30 (22%) 32 (20%) 0.54
  NT-proBNP, pg/mL, median (IQR) 852 (494–1404) 684 (376–999) 1145 (652–2067) <0.001
  Heart rate, bpm 69 (13) 69 (13) 69 (13) 0.97
  Body mass index, kg/m2 30 (6) 30 (6) 30 (6) 0.40
  Mean sitting systolic BP, mm Hg 135 (14) 133 (13) 136 (15) 0.13
  Mean sitting diastolic BP, mm Hg 77 (9) 80 (8) 75 (10) <0.001
  eGFR, mL/min per 1.73 m2 65 (20) 72 (21) 60 (18) <0.001
  eGFR <60 mL/min per 1.73 m2 125 (43%) 36 (28%) 89 (55%) <0.001
Baseline treatments
  Randomized to LCZ696 149 (50%) 73 (55%) 76 (46%) 0.16
  ACE inhibitors 162 (54%) 75 (56%) 87 (53%) 0.61
  ARBs 118 (40%) 55 (41%) 63 (38%) 0.64
  ACE inhibitors or ARBs 278 (93%) 129 (96%) 149 (91%) 0.06
  Diuretics 298 (100%) 134 (100%) 164 (100%)
  β-Blockers 235 (79%) 113 (84%) 122 (74%) 0.04
  Aldosterone antagonists 63 (21%) 25 (19%) 38 (23%) 0.34
Values are mean with SD and n (%) unless specified. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, 
estimated glomerular filtration rate; hs-TnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York 
Heart Association.
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Figure 2). The ratio of change in hs-TnT with LCZ696 in com-
parison with valsartan was 0.88 (95% confidence interval, 0.77–
1.00, P=0.05) at 12 weeks and 0.86 (95% confidence interval, 
0.75–0.99, P=0.03) at 36 weeks using an imputed value of half 
the lower limit of quantification in those with a hs-TnT below 
this limit. We observed a similar degree of reduction in hs-TnT 
by analyzing hs-TnT as a binary variable in a logistic regres-
sion model, as an ordinal variable in an ordinal logistic regres-
sion model, and after imputing a value for those under the limit 
of quantification that was closer to the limit of quantification 
of hs-TnT (Table 5). When repeated measures models were 
used, a consistent treatment effect of LCZ696 on hs-TnT levels 
was observed (Tables 4 and 5), with no significant interactions 
between treatment effect and follow-up time.
Discussion
In a well-characterized cohort of patients with HFPEF, we 
found that the majority of patients had a hs-TnT concentration 
above the threshold for diagnosis of myocardial injury. Higher 
hs-TnT concentrations were associated with several features 
that are known to be related to worse outcome in HFpEF, 
including increasing age, higher NT-proBNP, and lower eGFR, 
and were associated with abnormalities of cardiac structure. 
Treatment with the angiotensin receptor neprilysin inhibitor 
LCZ696 resulted in greater reduction in hs-TnT levels for 36 
weeks in comparison with treatment with valsartan, suggesting 
that LCZ696 may reduce this measure of myocardial injury in 
HFpEF via potentiation of natriuretic peptides17 (see below).
Although elevated troponin is now well described in HFrEF,3 
prior studies on the relationship between troponin and HFpEF 
have concentrated on patients who are hospitalized or acutely 
decompensated.8–10 Our population was similar to other trials 
of patients with HFpEF18 but generally younger with fewer 
comorbidities than community-based cohorts of patients 
with HFpEF.19 We found that 58% had a hs-TnT level in the 
myocardial injury range, a result similar to that observed in 
HFrEF. In the Controlled Rosuvastatin Multinational Trial in 
HF (CORONA), 49% of patients had a hs-TnT level above the 
limit for the detection of myocardial injury (0.014 μg/L) using 
a Roche assay.6 In the Valsartan Heart Failure Trial (Val-HeFT)7 
and the Gruppo Italiano per lo Studio della Sopravvivenza 
nell’Insufficienza Cardiaca-Heart Failure trial (GISSI-HF), 
Table 2. Echocardiographic Characteristics of the Cohort and by hs-TnT
Overall Cohort hs-TnT ≤0.014 μg/L hs-TnT >0.014 μg/L P Value
n=298 n=134 (45%) n=164 (55%)
hs-TnT ≤0.014 μg/L vs 
hs-TnT >0.014 μg/L
E′, cm/s 7.5 (2.7) 7.3 (2.6) 7.6 (2.9) 0.46
E/A 1.1 (0.6) 1.1 (0.6) 1.1 (0.7) 1.00
E/E′ 12.6 (6.0) 12.9 (6.4) 12.2 (5.5) 0.44
LA diameter, cm 3.7 (0.5) 3.6 (0.4) 3.8 (0.5) <0.05
LA volume, mL 67 (26) 64 (23) 69 (29) 0.17
Left atrial volume index, mL/m2 36 (13) 35 (12) 37 (15) 0.28
Left ventricular end-diastolic volume, mL 113 (29) 109 (29) 117 (28) 0.04
Left ventricular end-diastolic volume index, mL/m2 60 (14) 59 (15) 62 (13) 0.13
Left ventricular end-systolic volume, mL 48 (18) 46 (18) 49 (19) 0.28
Left ventricular end-systolic volume index, mL/m2 26 (9) 25 (10) 26 (9) 0.56
Left ventricular mass, g 145 (40) 134 (33) 157 (44) <0.001
Left ventricular mass index, g/m2 77 (21) 72 (18) 83 (23) <0.001
Relative wall thickness, % 0.37 (0.07) 0.36 (0.06) 0.37 (0.08) 0.24
Tricuspid regurgitant velocity, m/s 2.5 (0.4) 2.4 (0.4) 2.6 (0.4) 0.005
Left atrial global strain, % 21.1 (8.0) 21.2 (8.4) 21.1 (7.7) 0.91
Left ventricular global longitudinal strain, % –14.7 (3.3) –14.9 (3.4) –14.5 (3.3) 0.38
Left ventricular ejection fraction, % 58 (8) 58 (8) 58 (8) 0.66
Left ventricular ejection fraction ≥45% and <50% 37 (14%) 18 (14%) 19 (13%) 0.83
hs-TnT indicates high-sensitivity troponin T; and LA, left atrium.
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Figure 2. High-sensitivity troponin T (hs-TnT) levels by treatment 
group. Geometric mean (error bars represent 95% confidence 
intervals) of hs-TnT at baseline, 12 weeks, and 36 weeks by ran-
domized treatment. Adjusted P values for the effect of LCZ696 
vs valsartan on hs-TnT adjusted for the stratification variables 
of prior angiotensin-converting enzyme/angiotensin receptor 
blocker and region of randomization. hs-TnT analyzed imputing 
half the lower limit of quantification (<0.013 μg/L) for those with a 
value below the lower limit of quantification .
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47% and 64% of patients had a hs-TnT level above the limit of 
detection for myocardial injury (0.0135 μg/L) using a Roche 
hs-TnT assay.7 By comparison, in a population-based study of 
men and women aged 54 to 74 years, 7.4% of individuals had a 
hs-TnT in the myocardial injury range (>0.014 μg/L).20
Unlike ADHF where troponin elevation may be related to an 
acute precipitant, and acute decompensation can lead to vol-
ume overload and increased ventricular wall stress, the finding 
of elevated troponin in stable HFpEF is suggestive of ongo-
ing subclinical myocardial injury. Few patients had an acute 
precipitant to explain the troponin elevations. In the patients 
without a serious adverse event during the trial, 54% had a 
hs-TnT level in the injury range at baseline, 49% at 12 weeks, 
and 47% at 36 weeks. Furthermore, only 24% of patients with 
a hs-TnT in the injury range at 36 weeks had experienced 
a serious adverse event at any point in the study. However, 
ongoing myocardial injury may be part of the process that 
explains the high morbidity and mortality in HFpEF.21 The 
finding of increased left ventricular size and mass, increased 
left atrial size, and elevated NT-proBNP in patients with ele-
vated troponin suggests that increased wall stress may be a 
potential mechanism for the observed elevation. Stretching of 
myocytes can lead to the release of angiotensin II, increased 
oxidative stress, architectural rearrangement, and eventual 
cell death.22,23 Moreover, troponin can be released from viable 
myocytes when stretched or subjected to ischemia.24 Higher 
hs-TnT was also associated with higher myocardial mass and 
Table 3. Characteristics of Patients According to Whether hs-TnT Fell Was Unchanged or Increased at 36 wk
hs-TnT Fell hs-TnT Unchanged hs-TnT Increased
P for Trendn=72 n=81 n=72
Age, y 70±8 70±9 74±8 0.003
Women, % 36 (50%) 52 (65%) 43 (61%) 0.20
NYHA Class 0.09
  NYHA Class I 2 (3%) 0 (0%) 0 (0%)
  NYHA Class II 59 (82%) 69 (86%) 54 (76%)
  NYHA Class III 11 (15%) 11 (14%) 17 (24%)
Prior History
  Previous admission to hospital for heart failure 29 (40%) 29 (36%) 28 (39%) 0.92
  History of atrial fibrillation 29 (40%) 39 (49%) 32 (45%) 0.56
  Atrial fibrillation at screening ECG 17 (24%) 27 (34%) 23 (32%) 0.25
  History of hypertension 66 (92%) 78 (98%) 66 (93%) 0.74
  History of diabetes mellitus 29 (40%) 25 (31%) 27 (38%) 0.78
  History of myocardial infarction 15 (21%) 20 (25%) 13 (18%) 0.72
  NT-proBNP, pg/mL, median (IQR) 1148 (646–2148) 638 (364–999) 891 (601–1435) 0.18
  Heart rate, bpm 71±14 69±12 66±12 0.025
  Body mass index, kg/m2 30±6 31±6 31±5 0.58
  Mean sitting systolic BP, mm Hg 136±12 135±12 136±16 0.92
  Mean sitting diastolic BP, mm Hg 77±9 81±9 75±10 0.31
  eGFR, mL/min per 1.73 m2 63±18 75±20 60±18 0.55
  eGFR <60 mL/min per 1.73 m2 33 (46%) 18 (23%) 35 (49%) 0.68
Baseline treatments
  Randomized to LCZ696 40 (56%) 43 (54%) 31 (44%) 0.16
  ACE inhibitors 38 (53%) 42 (52%) 38 (54%) 0.93
  ARBs 28 (39%) 35 (44%) 31 (44%) 0.56
  ACE inhibitors or ARBs 66 (92%) 77 (96%) 67 (94%) 0.49
  β-blockers 51 (71%) 70 (88%) 57 (80%) 0.16
  Aldosterone antagonists 15 (21%) 15 (19%) 14 (20%) 0.87
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; hs-TnT, high-
sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart Association.
Table 4. Ratios of Change in hs-TnT in LCZ696 Group vs 
Valsartan Group at 12 and 36 wk Adjusted for Baseline hs-
TnT and the Stratification Variables of Region and Prior ACE 
Inhibitor or ARB Use
Primary Analysis
Ratio of Change in hs-TnT 
(LCZ696 vs Valsartan)
P 
Value
Linear regression of hs-TnT 
 at 12 wk (imputing 0.0065 μg/L)
0.88 (0.77–1.00) 0.05
Linear regression of hs-TnT  
at 36 wk (imputing 0.0065 μg/L)
0.86 (0.75–0.99) 0.03
Linear regression of hs-TnT— 
Repeated Measures Model  
(imputing 0.0065 μg/L)
0.87 (0.78–0.97) 0.01*
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor 
blocker; and hs-TnT, high-sensitivity troponin T.
*No significant interaction between in treatment effect and week of follow-up.
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tricuspid regurgitant velocity. The relative contribution of 
myocardial hypertrophy and fibrosis,25 the right heart,23,26 and 
the microcirculation and repetitive ischemia27 to the troponin 
concentrations observed remains to be determined.
We found that 36 weeks of therapy with LCZ696 compared 
with valsartan resulted in a modest reduction in troponin. 
These findings are consistent with the previously reported 
findings from the PARAMOUNT trial,14 including reduction 
of NT-proBNP at 12 weeks, and reduction in left atrial size 
and improvement in NYHA class at 36 weeks. This suggests 
that neprilysin inhibition by LCZ696 and potentiation of natri-
uretic peptides leading to a reduction in wall stress may reduce 
troponin leakage in parallel with reduction in NT-proBNP and 
left atrial size. Although change in hs-TnT correlated with 
change in systolic blood pressure, the effect of treatment on 
hs-TnT was independent of the changes in blood pressure in 
keeping with our prior observations on the action of the drug 
on NT-proBNP and echocardiographic parameters.28 Whether 
elevated troponin levels are associated with poorer prognosis 
in HFpEF is unknown, although this is likely given the associ-
ations that have been observed in HFrEF7 and possibly HFpEF 
in the acute decompensated setting.9 Moreover, whether a 
therapy that reduces hs-TnT levels would reduce morbidity 
and mortality in this population is unclear.
Some limitations of this analysis should be noted. 
PARAMOUNT was a relatively short-term study, and we thus 
cannot determine whether elevations in troponin are related to 
prognosis. Our data provide no direct insight into the mecha-
nisms of troponin release in HFpEF, although the relationship 
among troponin, cardiac structure, and NT-proBNP suggest 
that elevated wall stress may be a common mechanism to 
account for elevation in both biomarkers. With limited infor-
mation on right-sided hemodynamic indices, we cannot assess 
the contribution of the pulmonary vasculature and right side 
of the heart to the raised troponin levels we observed.26 Our 
cohort may represent patients with more severe HF as entry 
into the trial required an NT-proBNP level of >400 pg/mL. 
Therefore, our results may not be applicable to patients with 
HFpEF and low NT-proBNP levels. The ejection fraction in 
this trial was >50% in 86% of patients. We could not specifi-
cally examine those patients with an ejection fraction at the 
lower end of the ejection fraction spectrum (45% to 50%).
In summary, we observed elevation in hs-TnT in a well-char-
acterized HFpEF population, which was associated with larger 
left ventricular and atrial size, as well as higher NT-proBNP. 
These findings suggest that ongoing myocardial chronic tro-
ponin release, either because of myocyte stretch or injury, may 
contribute to the pathophysiology of HFpEF. LCZ696 reduced 
hs-TnT modestly compared with valsartan. Whether chronic 
reduction in hs-TnT can be achieved and whether this would 
lead to improved outcomes in HFpEF remains to be tested.
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CLINICAL PERSPECTIvE
Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with 
reduced ejection fraction, but less is known about the association in heart failure with preserved ejection fraction. In this 
analysis of the Prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin receptor blocker on 
Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) trial, we found that high-sensitivity tropo-
nin T (hs-TnT) was elevated in the myocardial injury range (>0.014 μg/L) in 55% of patients. Higher hs-TnT was associated 
with higher N-terminal pro-brain natriuretic peptide, lower estimated glomerular filtration rate, and larger left atrial size, left 
ventricular volume and mass. Treatment with the novel angiotensin receptor neprilysin inhibitor LCZ696 reduced hs-TnT to 
a greater extent at 12 weeks (12% reduction; P=0.05) and at 36 weeks (14% reduction; P=0.03) compared with valsartan. A 
large proportion of patients with heart failure with preserved ejection fraction in this trial had hs-TnT levels in the myocar-
dial injury range. Although hs-TnT was associated with abnormalities of cardiac structure, function, and elevated baseline 
N-terminal pro-brain natriuretic peptide, the finding that treatment with LCZ696 lowered hs-TnT in parallel with lowering 
N-terminal pro-brain natriuretic peptide and left atrial size suggest that the drug may also reduce this marker of myocardial 
injury in heart failure with preserved ejection fraction.
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